Pneumax is a biotechnology company developing next-generation therapeutics for pulmonary diseases using proprietary human-relevant preclinical models that integrate organ-on-a-chip technology, robotics, and advanced inhalation systems. By combining these technologies, the company enables more predictive evaluation of drug efficacy, safety, and delivery, accelerating the development of innovative therapies for patients with respiratory conditions.